Karen Mossman, professor in pathology and molecular medicine, has been named the University's associate vice-president, research.
McMaster's Board of Governors recently confirmed Mossman's appointment: Her term started September 1 and runs until June, 2022.
Prior to this appointment, Mossman was chair of the Department of Biochemistry and Biomedical Sciences for the Faculty of Health Sciences. She holds a joint appointment to the departments of biochemistry and biomedical sciences as well as pathology and molecular medicine.
As a professor, she teaches in the Bachelor of Health Sciences undergraduate program and mentors students in medical sciences, biochemistry, and the Biomedical Discovery and Commercialization program.
She also has extensive experience within a collaborative, multi-disciplinary environment, having worked with researchers, clinicians, clinician scientists and trainees.
"I'm interested in everything and I love learning, and I particularly love learning how others, be they colleagues or students, overcome challenges," she said.
"What I've learned during my time at McMaster is that everyone here is working toward being their best. In that regard, we all share a similar goal, and the most important thing is to learn from one another how we can achieve our individual and collective goals to advance our own work and, ultimately, McMaster's reputation."
Rob Baker, vice-president of research, says Mossman is the perfect fit for the role.
"Dr. Mossman brings an extraordinary blend of talents to the portfolio," he said.
"She's resourceful and intuitive; a team builder with an excellent track record in both research and administration, and has a solid understanding of the University, the granting agencies, and experience with industry collaboration and commercialization. I'm thrilled to have her as part of the research leadership team."
Mossman joined McMaster's Department of Pathology and Molecular Medicine in 2001. Her research focuses on understanding how viruses evade host immune defenses and how to use this knowledge for the development of oncolytic viruses for cancer immunotherapy.
She said she plans to stay engaged in her research and her lab, which currently boasts a team of a dozen research technicians, scientists, post-docs, graduate and undergraduate students.